Our mission is to translate the predictive power of proteomics into personalized care, making a difference in the lives of cancer patients worldwide.
OncoHost is a clinical stage precision oncology company developing the first of its kind Host Response Profiling platform (PROphetTM) for predicting responsiveness to cancer therapies.
Our technology analyzes proteomic changes in patient blood samples to detect signs of resistance to cancer therapies in real-time, enabling biomarker-guided treatment planning for physicians, target discovery for drug development and, ultimately, improved outcomes for patients.
The idea to develop Host Response profiling began with a burning question: why do cancer treatments help some patients but not others? In the early 2000’s, when the field of genomics was flourishing, our co-founder, Prof. Yuval Shaked, believed that patient and tumor genetics could not fully answer this question.
He believed that the complex interactions occurring between the body and drug could provide an additional dimension. His pioneering research demonstrated that although cancer therapies effectively destroy tumor cells, they also induce a range of unintended effects in healthy tissue, many of which paradoxically promote tumor aggressiveness. This phenomenon is known as the “Host Response” to cancer therapy.
OncoHost, founded in 2017, leverages the knowledge of the Host Response to overcome one of the major the challenges of clinical oncology today – resistance to therapy.
Dr. Ofer Sharon is a physician and entrepreneur with close to 20 years of experience in clinical and commercial product development for startups in the health tech, biotech, and medical device industries. Prior to joining Oncohost, he served multiple roles in global pharmaceutical companies including Medical Director for AstraZeneca (Israel), new technologies scout for Medimmune and Medical Director for MSD (Israel). He co-founded several healthcare companies, mainly focusing on bioinformatic and machine learning platforms for clinical deterioration detection and early intervention. Dr. Sharon is a Major (res.) in the IDF and a medical company commander with specific expertise in disaster relief. He received his MD cum laude from Tel Aviv University, Israel.
Dr. Morris Laster is a healthcare entrepreneur with close to 30 years of experience in the biopharmaceutical and medical device industry. He is known in the medical sector for his multiple senior executive positions. Currently, he is Co-Chairman and CEO of Scopus Biopharmaceuticals Inc, CEO of Clil Medical Ltd, a board member at Biondvax (NASDAQ:BVXV), and a medical venture partner and board member at OurCrowd. He has founded 6 publicly traded companies including Kitov Pharmaceuticals (TASE: KTOV), BioLineRx Ltd. (dually listed on NASDAQ and TASE:BLRX) and Keryx Biopharmaceuticals (NASDAQ:KERX). Dr. Laster received his MD from Downstate Medical Center, New York.
Co-Founder & Chief Scientific Advisor
Prof. Yuval Shaked leads an academic research laboratory at the Rappaport Faculty of Medicine of the Technion – Israel Institute of Technology. His pioneering research, which focuses on understanding tumor-host interactions and therapy-induced mechanisms of tumor progression, serves as the scientific basis for Oncohost’s technology. Prof. Shaked is currently head of the Technion Integrated Cancer Center and President of the International Cancer Microenvironment Society. Formerly, he served as Vice Dean for Research at the Rappaport Faculty of Medicine of the Technion. In addition, he is a member of several cancer societies, including American Association for Cancer Research (AACR), European Association of Cancer Research (EACR) and Israel Society of Cancer Research (ISCR). Prof. Shaked is author and co-author of over 100 peer-reviewed publications and 5 patents, and a recipient of multiple competitive research grants including the prestigious European Research Council (ERC) grants. For his achievements, he has received numerous awards including the Igal Alon fellowship award for starting junior faculty, the Krill Prize for Excellence in Scientific Research, and the Youdim Family Prize for Excellence in Cancer Research. He received his PhD in biochemistry from the Hebrew University of Jerusalem, Israel, and completed his post-doctoral training at Sunnybrook Health Sciences Centre, University of Toronto, Canada.
Chief Medical Officer
Prof. Adam Dicker is a leading radiation oncologist, serving as Senior Vice President and Chair of Enterprise Radiation Oncology, Director of the Jefferson Institute for Digital Health, and Professor of Radiation Oncology and Pharmacology and Experimental Therapeutics at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC). For his significant contributions to oncology research, education and patient care, Prof. Dicker has been named Fellow of the American Society of Clinical Oncology (FASCO) and Fellow of the American Society for Radiation Oncology (FASTRO). Among his numerous leadership positions are: Chair of the AACR’s Radiation Oncology Section of the Clinical Research Subcommittee; Chair of the ASCO-ASTRO Radiation Oncology Panel; Co-chair of NRG Oncology’s Translational Science and Digital Health committees; Co-Chair of the NCI Radiation Oncology Working Group; Editorial board member for several peer-reviewed journals.
Mr. Gideon Petrover has vast experience in multinational company management, operations, information technology and change management. He is a managing partner in Om-Maya, a private equity company, and a board member of several pharmaceutical and medical device companies.
VP Research and Development
Dr. Ella Fremder has over 10 years of combined industry and academic experience. Her areas of expertise include preclinical research, drug and medical device development, and team management. Prior to joining Oncohost, she was the Head of the R&D Biology Department at New Phase Ltd, an oncology drug and medical device company. Dr. Fremder received her PhD from the Technion – Israel Institute of Technology, where she also completed post-doctoral studies.
Chief Information Officer
Mr. Eran Issler has over 20 years of experience in the software industry. He specializes in medical information systems, with proven expertise in managing and developing software products for global customers. Prior to joining Oncohost, he was a product manager at OBG Soft, a fertility EMR management company, and senior system analyst at Maccabi Health Services. Mr. Issler holds an MSc in computer science (cum laude) and an MBA from the Technion – Israel Institute of Technology.
VP Clinical and Regulatory Affairs
Dr. Galit Yahalom has over 15 years of experience in the biotechnology industry, with a proven track record in end-to-end diagnostic product development, including R&D, clinical studies and regulatory submissions. She was a co-founder of, consultant for and CTO of several biomedical diagnostic companies. Dr. Yahalom holds a PhD in molecular biology from the Weizmann Institute of Science.
Intellectual Property Manager
Dr. Shani Raveh Shoval has 15 years of experience in biological research and intellectual property. Prior to joining Oncohost, she was a project manager at Pluristem therapeutics and intellectual property manager at Enzymotec. Dr. Shoval holds a PhD in molecular and cellular biology from the Weizmann Institute of Science.
Dr. Eyal Jacob has 15 years of experience in molecular, immunological and pre-clinical research. Prior to joining Oncohost, he was a project manager at Dyn Diagnostics, a medical device company. Dr. Jacob holds a PhD in immunology from the Technion – Israel Institute of Technology.
Dr. Michal Harel has over 8 years of experience in OMIC-level bioinformatic analysis, with strong expertise in working with proteomics data. Prior to joining Oncohost, Dr. Harel worked as a research associate at the Tel Aviv University. She received her PhD from the Weizmann Institute of Science, followed by a post-doctoral period at the Technion – Israel Institute of Technology.
Dr. Nili Dahan has over 10 years of experience in academic research and scientific writing. She holds a PhD in molecular and cellular biology from the Weizmann Institute of Science and was a post-doctoral fellow at the Technion – Israel Institute of Technology.
Head of Advisory Board
Dr. Aharon Schwartz is a distinguished pharmaceutical industry executive. He served in numerous senior positions at Teva Pharmaceutical Industries from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Currently he is the Chairman of BioLineRx (NASDAQ: BLRX) and a board member of Protalix (NASDAQ: PLX) and Foamix (NASDAQ: FOMX). Dr. Schwartz received a PhD in organic chemistry from the Weizmann Institute of Science in 1978, and a second PhD in 2014 from the Hebrew University of Jerusalem in the history and philosophy of science.
Prof. Raanan Berger is a senior oncologist and radiotherapist, serving as Director of the Cancer Center at the Sheba Medical Center, Israel. In 2006, he established the Riva Koschitzky Oncology Clinical Research Unit at Sheba, the largest center for all-phase oncology clinical trials in Israel, currently conducting over 200 advanced clinical trials. In addition, he is a senior lecturer at the Sackler Medical School at the Tel Aviv University, and runs a basic and translational research lab studying molecular mechanisms in prostate and breast tumorigenesis. Prof. Berger is a member of the European Society of Medical Oncology (ESMO) and American Society of Clinical Oncology (ASCO), and co-author of over 70 peer reviewed scientific articles. He received his MD and PhD from the Sackler Faculty of Medicine at the Tel Aviv University, Israel, and was a post-doctoral fellow at Dana Farber Cancer Institute, Harvard Medical School.
Prof. Michal Lotem is a senior physician and researcher, serving as Head of the Center for Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah University Hospital, and senior lecturer at the Faculty of Medicine, Hebrew University of Jerusalem. In parallel to intensive clinical work, she runs a scientific translational research lab focusing on tumor vaccines and cell-based immunotherapies for melanoma. She has co-authored over 70 peer-reviewed publications and is a member of several medical societies including the Melanoma Research Alliance, Society of Melanoma Research, European Association of Cancer Research (EACR), Israel Society of Cancer Research (ISCR) and Committee for Cell and Gene-based Therapy of the Israeli Ministry of Health. Prof. Lotem received her MD from the Sackler Faculty of Medicine at the Tel Aviv University, Israel, and was a research fellow at the National Institute of Health (NIH), Maryland, USA.
Dr. Orit Kaidar-Person is a radiation oncologist at Rambam Health Care Campus in Haifa, Israel. She serves as Chair of the Young Radiation Oncologists Group (YROG) of the European Organisation for Research and Treatment of Cancer (EORTC). Dr. Kaidar-Person received her medical degree from the Technion – Israel Institute of Technology, Faculty of Medicine and was a clinical fellow in the Department of Radiation Oncology at the University of North Carolina, School of Medicine, Chapel Hill, USA.
Prof. Robert Kerbel is a distinguished scientist at Sunnybrook Health Sciences Centre, University of Toronto, Canada. He is internationally recognized for his multiple contributions to cancer research, particularly in the fields of anti-angiogenic therapy and metronomic chemotherapy. For his achievements, Prof. Kerbel has been awarded the Canadian Cancer Society Robert Noble Award for Excellence in Cancer Research, the Breast Cancer Research Award from the European Institute of Oncology, a Man of Distinction Honor by the Israel Cancer Research Fund, and the Colin Thomson Memorial Medal from Worldwide Cancer Research. He was a recipient of a tier 1 Canada Research Chair in Tumor Biology, Angiogenesis and Antiangiogenic Therapy from 2001-2015. Prof. Kerbel is a member of numerous scientific advisory boards in both industry and academia as well as scientific peer review journal editorial boards. He also holds multiple sponsored research agreements with biotech and pharmaceutical companies. Prof. Kerbel received his PhD in immunology from Queen’s University in Kingston, Ontario, Canada in 1972, and completed postdoctoral training in tumor immunology at the Chester Beatty Research Institute in London, England.
Dr. Ellis is the The Ruben Distinguished Chair in Gastroenterology Cancer Research and a professor in the Departments of Surgical Oncology, and Molecular & Cellular Oncology at MDACC. He previously served as interim chair, Department of Cancer Biology (2008-2012), Director of the Metastasis Research Center (2010-2012), and Director of the Colorectal Cancer (CRC) Translational Research Program (2007-2013) at MDACC. He is currently Executive Director for Translational Medicine for MDACC’s Global Academic Program. Dr. Ellis has an active research laboratory that is focused on the biology of colorectal cancer and therapeutic targets. Dr. Ellis is active at the national level by playing leadership roles in ASCO and the AACR. He is currently a member of the ASCO Board of Directors. Dr. Ellis was co-program director of the AACR annual meeting in 2009 and 2011, and has served as course co-director of the AACR/ASCO Methods in Clinical Cancer Research Workshop (Vail Course, 2012-2014) and is currently co-director for the EORTC-ESMO-AACR-ECCO Methods in Clinical Cancer Research Workshop. Dr. Ellis serves as Vice Chair of SWOG, Translational Medicine, and Vice Chair of the Hope Foundation, SWOG’s philanthropic arm. He is currently co-chair of the National Cancer Institute’s (NCI) National Clinical Trials Network Core Correlative Sciences Committee. Dr. Ellis is also on the board of directors for the Canines-N-Kids Foundation. He currently serves on the ECOG/ACRIN data safety monitoring committees and the Scientific Audit Committee of the EORTC (Brussels, Belgium). Dr. Ellis is a Deputy Editor for JAMA Oncology.
Dr. Mario Sznol is Professor of Internal Medicine, Leader of the Melanoma-Renal Cancer Disease-Associated Translational Research Team, and Co-Leader of the Cancer Immunology Program. Dr. Sznol is also the current President of the Society for Immunotherapy of Cancer (SITC). Dr. Sznol graduated from Rice University and Baylor College of Medicine (BCM) in Houston, Texas. He trained in internal medicine at BCM and completed a medical oncology fellowship in the Department of Neoplastic Diseases, Mount Sinai Hospital, New York. He spent the next twelve years in the Biologics Evaluation Section (BES), Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program of the National Cancer Institute, and was Head of the BES from 1994-1999. He attended on the inpatient units of the Biological Response Modifiers Program, NCI, from 1988-1996 and the Immunotherapy Service of the Surgery Branch, NCI, from 1997-1999. From 1999-2004, he served as Vice President of Clinical Development and Executive Officer of Vion Pharmaceuticals in New Haven, Connecticut. Dr. Sznol’s areas of interest include early drug development, immunotherapy, and treatments for advanced melanoma and renal cancer.